The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020

Paolo A. Ascierto*, Michael B. Atkins, Alexander M. Eggermont, Jeffrey E. Gershenwald, Jean Jacques Grob, Omid Hamid, Vernon K. Sondak, Jeffrey A. Sosman, Hussein A. Tawbi, Jeffrey S. Weber, Corrado Caracò, Iman Osman, Igor Puzanov

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


The Great Debate session at the 2020 Melanoma Bridge virtual congress (December 3rd–5th, Italy) featured counterpoint views from experts on five specific controversial issues in melanoma. The debates considered whether or not innate immunity is important in the response to cancer and immunotherapy, how useful are the revised American Joint Committee on Cancer (AJCC) classification for the staging of patients, the use of sentinel node biopsy for staging patients, the use of triplet combination of targeted therapy plus immunotherapy versus combined immunotherapy, and the respective benefits of neoadjuvant versus adjuvant therapy. As is usual with Bridge congresses, the debates were assigned by meeting Chairs and positions taken by experts during the debates may not have necessarily reflected their own personal opinion.

Original languageEnglish (US)
Article number142
JournalJournal of Translational Medicine
Issue number1
StatePublished - Dec 2021


  • Adjuvant
  • Anti-CTLA-4
  • Anti-PD-1
  • BRAF inhibitor
  • Immunotherapy
  • MEK inhibitor
  • Melanoma
  • Neoadjuvant
  • Staging
  • Targeted therapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020'. Together they form a unique fingerprint.

Cite this